TNFRSF9 and neoplasm: ,71 Therapeutic approaches aimed at normalizing tumour hypoxia (e.g. supplemental oxygenation and hypoxia-activated prodrugs) or targeting hypoxia-inducible factor-1α-induced pathways such as CD137, can re-programme the TME, promote tumour regression and sensitize tumours to ICIs in vivo.63,66,71,72